Insight into the biology of Macrophage Migration Inhibitory Factor (MIF) revealed by the cloning of its cell surface receptor

Cell Research

Volumn 16, Issue 2, 2006, Pages 162-168

  Leng, Lin ^a   Bucala, Richard ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ERK 1 2; MIF; MIF receptor

Indexed keywords

B LYMPHOCYTE ANTIGEN; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN RECEPTOR; MACROPHAGE MIGRATION INHIBITION FACTOR; MACROPHAGE MIGRATION INHIBITORY FACTOR RECEPTOR;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CONFERENCE PAPER; GENETICS; HUMAN; INVARIANT CHAIN; METABOLISM; MOLECULAR CLONING; PHYSIOLOGY; PROTEIN QUATERNARY STRUCTURE; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CLONING, MOLECULAR; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MODELS, MOLECULAR; PROTEIN STRUCTURE, QUATERNARY; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 32644454746     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/sj.cr.7310022     Document Type: Conference Paper

References (61)

1. George M, Vaughn JH. In vitro cell migration as a model for delayed hypersensitivity. Proc Soc Exptl Biol Med 1962; 111:514-21.
2. David J. Delayed hypersensitivity in vitro: Its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A 1966; 56:72-7.
3. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966; 153:80-2.
4. Weiser WY, Temple PA, Witek-Giannotti JS, Remold HG, Clark SC, David JR. Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A 1989; 86:7522-6.
5. Bernhagen J, Calandra T, Mitchell RA, et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993; 365:756-9.
6. Sugimoto H, Suzuki M, Nakagawa A, Tanaka I, Nishihira J. Crystal structure of macrophage migration inhibitory factor from human lymphocyte at 2.1 A resolution. FEBS Letters 1996; 389:145-8.
7. Sun HW, Bernhagen J, Bucala R, Lolis E. Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A 1996; 93:5191-6.
8. Kato Y, Muto T, Tomura T, et al. The crystal structure of human glycosylation-inhibiting factor is a trimeric barrel with three 6-stranded beta-sheets. Proc Natl Acad Sci U S A 1996; 93:3007-10.
9. Rosengren E, Bucala R, Aman P, et al. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Molecular Medicine 1996; 2:143-9.
10. Swope MD, Lolis E. Macrophage Migration Inhibitory Factor: Cytokine, Hormone, or Enzyme. Rev Physiol Biochem Pharmacol 1999; 139:1-32.
11. Swope M, Sun HW, Blake PR, Lolis E. Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor. EMBO J 1998; 17:3534-41.
12. Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M, Nishihira J. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J Biol Chem 2000; 275:444-50.
13. Bendrat K, Al-Abed Y, Callaway DJ, et al. Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry 1997; 36:15356-62.
14. Hermanowski-Vosatka A, Mundt SS, Ayala JM, et al. Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis and random migration. Biochemistry 1999; 38:12841-949.
15. Senter PD, Al-Abed Y, Metz CN, et al. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc Natl Acad Sci U S A 2002; 99:144-9.
16. Bucala R. MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. FASEB J 1996; 10:1607-13.
17. Mitchell RA, Metz CN, Peng T, Bucala R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 1999; 274:18100-6.
18. Luttrell LM, Daaka Y, Lefkowitz RJ. Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr Opin Cell Biol 1999; 11:177-83.
19. Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem 1998; 273:19925-8.
20. Marshall C. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal regulated kinase activation. Cell 1995; 80:179-85.
21. Howe AK, Juliano RL. Distinct mechanisms mediate the initial and sustained phases of integrin-mediated activation of the Raf/ MEK/mitogen-activated protein kinase cascade. J Biol Chem 1998; 273:27268-74.
22. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin al-phavbeta3 requirement for sustained mitogen activated protein kinase activity during angiogenesis. J Cell Biol 1998; 140:1255-63.
23. Roovers K, Davey G, Zhu X, Bottazzi ME, Assoian RK. Al-pha5beta1 integrin controls cyclin D1 expression by sustaining mitogen-activated protein kinase activity in growth factor-treated cells. Mol Cell Biol 1999; 10:3197-204.
24. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997; 9:180-6.
25. Roger T, David J, Glauser MP, Calandra T. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 2001; 414:920-4.
26. Murakami M, Nakatani Y, Atsumi G, Inoue K, Kudo I. Regulatory functions of phospholipase A2. Crit Rev Immunol 1997; 17:225-83.
27. Swantek J L, Cobb MH, Geppert TD. Jun N-terminal kinase/stress activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-a) translation: glucocorticoids inhibit TNF-a translation by blocking JNK/SAPK. Mol Cell Biol 1997; 17:6274-82.
28. Goppelt-Struebe M, Rehfeldt W. Glucocorticoids inhibit TNF alpha-induced cytosolic phospholipase A2 activity. Biochim Biophys Acta 1992; 1127:163-7.
29. Roger T, Chanson AL, Knaup-Reymond M, Calandra T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur J Immunol 2005; 35:3405-13.
30. Kleemann R, Kapurniotu A, Mischke R, Held J, Bernhagen J. Characterization of catalytic center mutants of macrophage migration inhibitory factor (MIF) and comparison to Cys81Ser MIF. Eur J Biochem 1999; 261:753-66.
31. Leng L, Metz C, Fang Y, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003; 197:1467-76.
32. Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 1994; 12:259-93.
33. Naujokas MF, Morin M, Anderson MS, Peterson M, Miller J. The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 1993; 74:257-68.
34. Naujokas MF, Arneson LS, Fineschi B, et al. Potent effects of low levels of MHC class II associated invariant chain on CD4+ T cell development. Immunity 1995; 3:359-72.
35. Jasanoff A, Wagner G, Wiley DC. Structure of a trimeric domain of the MHC class II-associated chaperonin and targeting protein Ii. EMBO J 1998; 17:6812-8.
36. Shachar I, Flavell RA. Requirement for invariant chain in B cell maturation and function. Science 1996; 274:106-8.
37. Ashman JB, Miller J. A role for the transmembrane domain in the trimerization of the MHC Class II-associated invariant chain. J Immunol 1999; 163:2704-12.
38. Sant AJ, Cullen SE, Schwartz BD. Biosynthetic relationships of the chondroitin sulfate proteoglycan with Ia and invariant chain glycoproteins. J Immunol 1985; 135:416-22.
39. Sant AJ, Cullen SE, Giacoletto KS, Schwartz BD. Invariant chain is the core protein of the Ia-associated chondroitin sulfate proteoglycan. J Exp Med 1985; 162:1916-34.
40. Koch H, Harris AW. Differential expression of the invariant chain in mouse tumor cells: relationship to B lymphoid development. J Immunol 1984; 132:12-5.
41. Henne C, Schwenk F, Koch N, Möller P. Surface expression of the invariant chain (CD74) is independent of concomitant expression of major histocompatibility complex class II antigens. Immunol 1995; 84:177-82.
42. Arunachalam B, Lamb C, Cresswell P. Transport properties of free and MHC class II-associated oligomers containing different isoforms of human invariant chain. Int Immunol 1993; 6:451.
43. Bozza M, Satoskar AR, Lin G, et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 1999; 189:341-6.
44. Honma N, Kosecki H, Akasaka T, et al. Deficiency of the MIF gene has no significant effect on endotoxaemia. Immunology 2000; 100:84-90.
45. Fingerle-Rowson G, Satoskar A, Bucala R. Macrophage migration inhibitory factor (MIF)-deficient mice. In: Cytokine Knockouts (G. Fantuzzi, Ed.). Humana Press: Totowa NJ 2003.
46. Fingerle-Rowson G, Petrenko O, Netz CN, et al. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci U S A 2003; 100:9354-9.
47. Mizue Y, Ghani S, Leng L, et al. Role for Macrophage Migration Inhibitory Factor (MIF) in Asthma. Proc Natl Acad Sci U S A 2005; 102:14410-5.
48. Topilski I, Harmelin A, Flavell RA, Levo Y, Shachar I. Preferential Th1 immune response in invariant chain-deficient mice. J Immunol 2002; 168:1610-7.
49. Matza D, Kerem A, Medvedovsky H, Lantner F, Shachar I. Invariant chain-induced B cell differentiation requires intramembrane proteolytic release of the cytosolic domain. Immunity 2002; 17:549-60.
50. Matza D, Kerem A, Shachar I. Invariant chain, a chain of command. Trends in Immunology 2003; 24:264-8.
51. Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: A control mechanism conserved from bacteria to humans. Cell 2000; 100:391-8.
52. Urban S, Freeman M. Intramembrane proteolysis controls diverse signalling pathways throughout evolution. Curr Opin Gen Dev 2002; 12:512-8.
53. II105-NF-kB-dependent transcription program. J Biol Chem 2001; 276:27203-6.
54. Anderson HA, Bergstralh DT, Kawamura T, Blauvelt A, Roche PA. Phosphorylation of the invariant chain by protein kinase C regulates MHC class II trafficking to antigen-processing compartments. J Immunol 1999; 163:5435-43.
55. Lesley J, Hyman R, Kincade P. CD44 and its interaction with extracellular matrix. Adv Immunol 1993; 54:271-335.
56. Meyer-Siegler KL, Leifheit EC, Vera PL. Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer 2004; 4.
57. Stroud RM, LaPorte S, Wells JA. Cytokine-receptor signaling at the structural level. In: Cytokine Reference Vol 1: Ligands (J. J. Oppenheim and M. Feldmann, Eds.). Academic Press: San Diego, 2001.
58. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997; 15:797-819.
59. Turley EA, Noble PW, Bourguignon LYW. Signaling properties of hyaluronan receptors. J Biol Chem 2002; 277:4589-92.
60. Hudson JD, Shoaibi MA, Maestro R, et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999; 190:1375-82.
61. Mitchell RA, Liao H, Chesney J, et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A 2002; 99:345-50.